285 related articles for article (PubMed ID: 27133076)
1. Virtual screening based on pharmacophore model followed by docking simulation studies in search of potential inhibitors for p38 map kinase.
Shahlaei M; Doosti E
Biomed Pharmacother; 2016 May; 80():352-372. PubMed ID: 27133076
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Novel Glucagon Receptor Antagonists Using Combined Pharmacophore Modeling and Docking.
Jafari F; Nowroozi A; Shahlaei M
Iran J Pharm Res; 2018; 17(4):1263-1287. PubMed ID: 30568686
[TBL] [Abstract][Full Text] [Related]
4. Identification of p38α MAP kinase inhibitors by pharmacophore based virtual screening.
Gangwal RP; Das NR; Thanki K; Damre MV; Dhoke GV; Sharma SS; Jain S; Sangamwar AT
J Mol Graph Model; 2014 Apr; 49():18-24. PubMed ID: 24473068
[TBL] [Abstract][Full Text] [Related]
5. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
[TBL] [Abstract][Full Text] [Related]
6. Constructing an atomic-resolution model of human P2X7 receptor followed by pharmacophore modeling to identify potential inhibitors.
Ahmadi M; Nowroozi A; Shahlaei M
J Mol Graph Model; 2015 Sep; 61():243-61. PubMed ID: 26298810
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
8. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking.
Lee YH; Yi GS
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30336555
[TBL] [Abstract][Full Text] [Related]
10. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
11. p38 Mitogen-activated protein kinase inhibitors: a review on pharmacophore mapping and QSAR studies.
Gangwal RP; Bhadauriya A; Damre MV; Dhoke GV; Sangamwar AT
Curr Top Med Chem; 2013; 13(9):1015-35. PubMed ID: 23651481
[TBL] [Abstract][Full Text] [Related]
12. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
13. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
Vyas VK; Ghate M; Goel A
J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
[TBL] [Abstract][Full Text] [Related]
15. Homology modeling and virtual screening for inhibitors of lipid kinase PI(4)K from Plasmodium.
Ren JX; Gao NN; Cao XS; Hu QA; Xie Y
Biomed Pharmacother; 2016 Oct; 83():798-808. PubMed ID: 27490781
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
Panicker PS; Melge AR; Biswas L; Keechilat P; Mohan CG
Chem Biol Drug Des; 2017 Oct; 90(4):629-636. PubMed ID: 28303669
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
Bhojwani HR; Joshi UJ
Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
[TBL] [Abstract][Full Text] [Related]
18. Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors.
Gangwal RP; Damre MV; Das NR; Dhoke GV; Bhadauriya A; Varikoti RA; Sharma SS; Sangamwar AT
J Mol Graph Model; 2015 Apr; 57():89-98. PubMed ID: 25687765
[TBL] [Abstract][Full Text] [Related]
19. Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis.
Pathak D; Chadha N; Silakari O
J Mol Graph Model; 2016 Nov; 70():85-93. PubMed ID: 27693947
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies.
Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA
Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
